Table 1.

Prevalent Antihypertensive and Statin User Characteristics

Antihypertensive Users	–	–
Variable, mean ± SD	Dementia, Casesd (n = 292)	Non-Dementia, Controls (n = 3890)
Age (at anchor datea), years	82.3 ± 5.4	80.9 ± 4.9
Female sex, n (%)	201 (68.8)	3095 (79.6)
Years of education	14.0 ± 2.8	14.1 ± 2.9
Charlson risk scoreb	1.8 ± 2.1	1.6 ± 1.9
Years of antihypertensive use (prior to anchor date)	16.2 ± 9.2	16.3 ± 9.1
Proportion of Days Covered (PDC)c	0.88 ± 0.15	0.92 ± 0.13
Statin Users	–	–
Variable, mean ± SD	Dementia, Casese (n= 148)	Non-Dementia, Controls (n = 1131)
Age (at anchor datea), years	81.4 ± 5.2	79.8 ± 5.8
Female sex, n (%)	77 (52.0)	568 (50.2)
Years of education	14.3 ± 3.0	14.8 ± 3.0
Charlson risk scoreb	2.1 ± 1.9	2.0 ± 2.1
Years of statin use (prior to anchor date)	5.7 ± 4.1	5.4 ± 4.0
Proportion of Days Covered (PDC)c	0.83 ± 0.17	0.85 (0.17)

Abbreviations: SD, standard deviation

^aThe index date was the date of dementia onset for cases, while for matched controls it was a study visit date at similar ACT follow-up time as the case’s dementia onset (within +/− 1 year). The anchor date was defined as three years before the index date

^bBased on outpatient, inpatient, and emergency room utilization data

^cDefined over 3 years, from anchor date to index date

^dDementia sub-type prevalence for cases in antihypertensive model: 59% Alzheimer’s disease type, 10% vascular, 22% multiple etiologies, 9% other. Age-specific dementia and Alzheimer’s disease incidence rates from the ACT Study are similar to those found in many other studies¹⁷

^eDementia sub-type prevalence for cases in statin model: 50% Alzheimer’s disease type, 11% vascular, 28% multiple etiologies, 11% other. Age-specific dementia and Alzheimer’s disease incidence rates from the ACT Study are similar to those found in many other studies¹⁷